Development of therapeutic Vaccibody cancer vaccines against various classes of tumor antigens
1 Formål
Nykode Therapeutics ASA is dedicated to the discovery and development of novel cancer vaccines. Nykode has developed a versatile vaccine platform using its proprietary NeoSELECT™ bioinformatics platform to identify broad class of cancer antigens derived from somatic mutations in cancer cell genomes. Nykode's vaccine platform is highly versatile and the DNA vaccine can be adopted to encode varying numbers of high-quality tumor antigens that activates the immune system to attack and reject the tumor. The purpose of this experiment is to assess ability of the Nykode's plasmid vaccine that encodes various classes of tumor antigens predicted by the NeoSELECT™ to prevent tumor growth in vivo in mouse models. Furthermore, in the follow-up experiments we will test the synergistic effect of the check point inhibitor (CPIs) antibodies includes anti-PD-1 and anti-PD-L1 along with the most promising plasmid vaccines in preventing tumor growth.
2 Skadevirkninger
The vaccination method used to deliver DNA gives mild pain both during and after vaccination. We expect the tumor growth over the experimental period induce moderate stress to the animals. Otherwise no adverse effect on the animal is expected.
3 Forventet nytteverdi
Nykode Therapeutics is a world leader in designing safe cancer vaccines that are unique to tumor type and showed promising data from two clinical trials targeting various indications. The proof-of-principle data that we generate through this pre-clinical trial in mouse models will validate our bioinformatic platform-based identification of multiple types of cancer antigens and will provide mechanistic insight into the immune system activation and tumor rejection. The pre-clinical experiments will provide an opportunity for Nykode to submit applications to conduct DNA vaccine-based immunotherapy in clinical trials, to provide the new line of treatment opportunities for cancer patients.
4 Antall dyr og art
In this proposed experiment, we will use 1020 mice (Mus musculus), Strain/Line: C57BL/6, BALB/c.
5 Hvordan etterleve 3R
The in vivo experiments in mice are the only available option to evaluate the therapeutic efficacy of the DNA vaccines that induce T cell immune responses against tumor cells that results in tumor protection. Prior to tumor challenge experiments, we will screen several Nykode DNA constructs that encodes various types of tumor antigens alone or in various combination to determine their efficacy in activating T cell immune responses in a less stressful/painful experiment (FOTS ID 26310) that will reduce the number of treatment groups and animals used in the tumor challenge experiments. Furthermore, our extensive expertise with this type of mice experiments as well as the experimental design in published studies indicate that it is appropriate with the number of animals outlined to observe significant differences between the groups in the experiment.
Nykode Therapeutics ASA is dedicated to the discovery and development of novel cancer vaccines. Nykode has developed a versatile vaccine platform using its proprietary NeoSELECT™ bioinformatics platform to identify broad class of cancer antigens derived from somatic mutations in cancer cell genomes. Nykode's vaccine platform is highly versatile and the DNA vaccine can be adopted to encode varying numbers of high-quality tumor antigens that activates the immune system to attack and reject the tumor. The purpose of this experiment is to assess ability of the Nykode's plasmid vaccine that encodes various classes of tumor antigens predicted by the NeoSELECT™ to prevent tumor growth in vivo in mouse models. Furthermore, in the follow-up experiments we will test the synergistic effect of the check point inhibitor (CPIs) antibodies includes anti-PD-1 and anti-PD-L1 along with the most promising plasmid vaccines in preventing tumor growth.
2 Skadevirkninger
The vaccination method used to deliver DNA gives mild pain both during and after vaccination. We expect the tumor growth over the experimental period induce moderate stress to the animals. Otherwise no adverse effect on the animal is expected.
3 Forventet nytteverdi
Nykode Therapeutics is a world leader in designing safe cancer vaccines that are unique to tumor type and showed promising data from two clinical trials targeting various indications. The proof-of-principle data that we generate through this pre-clinical trial in mouse models will validate our bioinformatic platform-based identification of multiple types of cancer antigens and will provide mechanistic insight into the immune system activation and tumor rejection. The pre-clinical experiments will provide an opportunity for Nykode to submit applications to conduct DNA vaccine-based immunotherapy in clinical trials, to provide the new line of treatment opportunities for cancer patients.
4 Antall dyr og art
In this proposed experiment, we will use 1020 mice (Mus musculus), Strain/Line: C57BL/6, BALB/c.
5 Hvordan etterleve 3R
The in vivo experiments in mice are the only available option to evaluate the therapeutic efficacy of the DNA vaccines that induce T cell immune responses against tumor cells that results in tumor protection. Prior to tumor challenge experiments, we will screen several Nykode DNA constructs that encodes various types of tumor antigens alone or in various combination to determine their efficacy in activating T cell immune responses in a less stressful/painful experiment (FOTS ID 26310) that will reduce the number of treatment groups and animals used in the tumor challenge experiments. Furthermore, our extensive expertise with this type of mice experiments as well as the experimental design in published studies indicate that it is appropriate with the number of animals outlined to observe significant differences between the groups in the experiment.